Animal virology

Mediaplanet and Flu Survivor Latasha Haynes Team Up for Fighting the Flu

Retrieved on: 
Tuesday, December 8, 2020
Medical specialties, Influenza A virus subtype H1N1, Influenza vaccine, Health care, Medicine, Influenza, Animal virology

NEW YORK, Dec. 8, 2020 /PRNewswire-PRWeb/ -- Helping to conclude National Influenza Vaccination Week, Mediaplanet today announces the launch of this December's edition of "Fighting the Flu."

Key Points: 
  • NEW YORK, Dec. 8, 2020 /PRNewswire-PRWeb/ -- Helping to conclude National Influenza Vaccination Week, Mediaplanet today announces the launch of this December's edition of "Fighting the Flu."
  • While most people fully recover from bouts of flu, in some cases the illness can become extremely dangerous or even fatal.
  • Haynes' near-death experience with the flu inspired her to become an advocate with Families Fighting Flu (FFF), a national, nonprofit advocacy organization that's dedicated to protecting children, families, and communities against the flu.
  • As part of this campaign, Haynes is sharing her story and what you can do to prevent flu.

Global Influenza Vaccine Markets, 2020-2025 by Age Group, Vaccine Type, Valency, Distribution Channel, Geography and the Impact of Covid-19 with Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 8, 2020
Health, General Health, Health, Articles, Animal virology, Influenza, Pandemic, Spanish flu, Orthomyxoviridae, Influenza A virus subtype H5N1, Swine influenza

The "Global Influenza Vaccine Market (2020-2025), By Age Group, Vaccine Type, Valency, Distribution Channel, Geography and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Influenza Vaccine Market (2020-2025), By Age Group, Vaccine Type, Valency, Distribution Channel, Geography and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Flu is a contagious respiratory illness caused by the influenza virus that affects the nose, throat, and sometimes the lungs.
  • Fever, cough, sore throat, runny or stuffy nose, muscle or body aches, headaches, fatigue are the common symptoms of the disease.
  • Influenza A virus is the only influenza virus known to cause flu pandemics, i.e., global epidemics of flu disease.

OncoMyx Announces Assignment of Foundational Technology and Intellectual Property Portfolio for Oncolytic Myxoma Virus Technology

Retrieved on: 
Monday, December 7, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medicine, Animal virology, Health sciences, Clinical medicine, Experimental cancer treatments, Biotechnology, Chordopoxvirinae, Myxoma virus, Myxomatosis, Virotherapy, Oncolytic virus, Virus, Myxoma Virotherapy for the Treatment of Cancer, OncoMyx Therapeutics

The assignment of this technology and intellectual property to OncoMyx further reinforces our IP portfolio protecting our use of myxoma virus and our pipeline of myxoma virotherapies for the treatment of cancer, said Steve Potts, Ph.D., MBA, cofounder and chief executive officer of OncoMyx.

Key Points: 
  • The assignment of this technology and intellectual property to OncoMyx further reinforces our IP portfolio protecting our use of myxoma virus and our pipeline of myxoma virotherapies for the treatment of cancer, said Steve Potts, Ph.D., MBA, cofounder and chief executive officer of OncoMyx.
  • I am pleased that OncoMyx has been assigned the patent rights associated with the pioneering myxoma research that was done at Western, as the myxoma virus is unique as a technology platform to build oncolytic immunotherapies.
  • Because myxoma virus is not pathogenic to humans, myxoma virotherapy does not have to overcome pre-existing immunity.
  • OncoMyx Therapeutics develops oncolytic immunotherapies based on the myxoma virus (MYXV) platform to orchestrate an immune response to better treat cancer.

Innovation Pharmaceuticals COVID-19 Clinical Trial to Support Additional Development of Brilacidin as a “Pan-Coronavirus” Therapeutic

Retrieved on: 
Monday, November 30, 2020
Animal virology, Zoonoses, Coronavirus, Veterinary medicine, Severe acute respiratory syndrome coronavirus, Virology, Health sciences

Research shows Brilacidin exerted potent in vitro inhibition of multiple strains of H-CoVs.

Key Points: 
  • Research shows Brilacidin exerted potent in vitro inhibition of multiple strains of H-CoVs.
  • The Company is evaluating these data alongside previously obtained SARS-CoV-2 data, strategizing with its scientific advisors and consultants, to develop Brilacidin as a pan-coronavirus therapeutic.
  • The Company is planning to conduct additional in vitro and in vivo Brilacidin studies on multiple coronaviruses, to further inform the drugs anti-coronavirus properties and prepare for potential future clinical testing.
  • Collectively, these data support Brilacidin as a unique 3 in 1 combinationantiviral, immuno/anti-inflammatory, and antimicrobialCOVID-19 therapeutic candidate.

Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person

Retrieved on: 
Monday, November 23, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Chemical compounds, Organic compounds, Medical specialties, Animal virology, Prodrugs, Influenza, Baloxavir marboxil, Influenza treatment, Influenza vaccine, BLOCKSTONE, Xofluza® (baloxavir marboxil), Genentech in Influenza, Genentech

BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.

Key Points: 
  • BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza.
  • Xofluza showed a statistically significant prophylactic effect on influenza after a single oral dose in people exposed to an infected household contact.
  • Xofluza is also approved for post-exposure prophylaxis of influenza in people 12 years of age and older following contact with an individual who has influenza.
  • Prevent the flu in people 12 years of age and older following contact with a person who has the flu.

Avian influenza: virus spreading rapidly in Europe

Retrieved on: 
Friday, November 20, 2020
Animal virology, Veterinary medicine, Health sciences, Health, Influenza A virus subtype H5N1, Agricultural health and safety, Avian influenza, Influenza, Influenza pandemic

The risk of avian influenza moving into previously unaffected European countries is high, according to an update published today by EFSA which shows that the virus is spreading rapidly across the continent.

Key Points: 
  • The risk of avian influenza moving into previously unaffected European countries is high, according to an update published today by EFSA which shows that the virus is spreading rapidly across the continent.
  • The majority of the detections were in wild birds although there have been a handful of outbreaks in poultry.
  • The new report rates the likelihood of the virus spreading from wild birds to poultry as high.
  • The report was produced with the support of the European Centre for Disease Prevention and Control (ECDC) and the European Reference Laboratory for Avian Influenza.

Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action

Retrieved on: 
Friday, November 20, 2020
Health sciences, Health, Medicine, 3C-like protease, Sarbecovirus, Animal virology, Coronavirus, Virus, 3CLpro-1, Viral nonstructural protein

The researchers believe the 3CL protease plays a key role in coronavirus activity and is critical to allow for processing of the proteins encoding viral RNA.

Key Points: 
  • The researchers believe the 3CL protease plays a key role in coronavirus activity and is critical to allow for processing of the proteins encoding viral RNA.
  • Inhibition of this activity could stop the ability of coronaviruses to replicate, and thus inhibit their ability to spread in the body.
  • During the study it was shown that Tollovid, which is an extract of a botanical substance, was able to successfully inhibit the 3CL protease activity.
  • There has been overwhelmingly positive customer feedback on their experience with the product, including significant positive feedback from physicians.

Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine

Retrieved on: 
Thursday, November 19, 2020
Health, Medical specialties, Medicine, Vaccines, Influenza, Influenza vaccine, Animal virology, Live attenuated influenza vaccine, Vaccine, Swine influenza, Swine flu pandemic in the United States, Swine flu pandemic

Under the terms of the deal, Generex will receive an upfront payment of $2.5 million to initiate the Ii-Key vaccine development work to identify swine flu epitopes for a new Ii-Key vaccine.

Key Points: 
  • Under the terms of the deal, Generex will receive an upfront payment of $2.5 million to initiate the Ii-Key vaccine development work to identify swine flu epitopes for a new Ii-Key vaccine.
  • The current plan is to incorporate the Ii-Key-H1 vaccine into the seasonal influenza vaccine to create a Complete Vaccine across influenza strains.
  • Upon commercialization, Generex will receive a royalty on sales of the influenza vaccine.
  • Then, with the 2009 swine flu outbreak, Generex revitalized the Ii-Key vaccine program with the Ii-Key-H1 vaccine, using the H5 vaccine which is 100% homologous (the same) between the avian and swine influenza strains.

xCures launches xACCESS - A new module in their AI-assisted clinical platform

Retrieved on: 
Tuesday, November 17, 2020
Health sciences, Health, Branches of biology, Clinical pharmacology, Clinical research, Drug discovery, Pharmaceutical industry, Animal virology, Bovine viral diarrhea, Clinical trial, Mitogen-activated protein kinase, Oncology

SAN FRANCISCO, Nov. 17, 2020 /PRNewswire/ -- Today, xCures Inc. is launching xACCESS - a new registration module for their AI-assisted clinical study platform.

Key Points: 
  • SAN FRANCISCO, Nov. 17, 2020 /PRNewswire/ -- Today, xCures Inc. is launching xACCESS - a new registration module for their AI-assisted clinical study platform.
  • The xCures platform uses a Master Observational Registry to efficiently run a wide variety of oncology studies and decentralized trials, prospectively generating real-world evidence.
  • "xACCESS is xCures' first patient-centric technology module, onboarding patients directly to our sponsored studies and partner programs," stated Mika Newton, xCures' CEO.
  • The xACCESS module will be used for all clinical studies and programs available on the xCures platform, including the recently announced Compassionate Use program for ulixertinib (BVD-523), currently enrolling patients with MAPK pathway aberrant cancer.

SEKISUI Diagnostics Announces Launch of the OSOM® Ultra Plus Flu A&B Test in Europe

Retrieved on: 
Tuesday, November 17, 2020
Animal virology, Medical specialties, Influenza A virus, Zoonoses, Influenza, Medicine, Infectious diseases

Burlington, Massachusetts, Nov. 17, 2020 /PRNewswire/ -- SEKISUI Diagnostics announces it has received CE Marking (Conformit Europenne) for the OSOM Ultra Plus Flu A&B Test and has begun marketing in Europe.

Key Points: 
  • Burlington, Massachusetts, Nov. 17, 2020 /PRNewswire/ -- SEKISUI Diagnostics announces it has received CE Marking (Conformit Europenne) for the OSOM Ultra Plus Flu A&B Test and has begun marketing in Europe.
  • The test utilizes traditional lateral flow technology with performance near or exceeding sensitivity of other reader-based tests without using an instrument.
  • "The CE Marking of the OSOM Ultra Plus Flu A&B Testexpands our flu portfolio allowing us to provide a more accurate rapid influenza test kitto many different institutions in more countries.
  • SEKISUI Diagnostics isa global diagnostics company committed to improving patient's lives by providing innovative medical diagnostics to physicians and laboratories through a global commercial network.